Why Apple may change EHRs for the better

Adding health records to Apple’s health app didn’t excite advocates for greater patient access to their medical data, but Harvard Medical School professor Ken Mandl, MD, MPH, argues it could be a major breakthrough in promoting sharing of health records and eventually allow patients to see all their health data collected from many different sources.

Writing for CNBC, Mandl said previous efforts he was involved in to “shake loose data from the computer systems in doctors' offices” didn’t pan out. Apple’s effort could because on the rampant expansion in health IT over the past decade and its use of a program Mandl helped create called SMART, which can make electronic health records (EHRs) “work like iPhones do.”

“Apple uses SMART to connect the health app to hospitals and doctors' offices,” he wrote. “The good news for patients, doctors and innovators is that Apple chose a standardized, open connection over a proprietary, closed one. This approach lets any other app, whether running on the web, iPhone, or Android, use that same interface to connect. So Apple will compete on value and customer satisfaction, rather than on an exclusive lock on the data.”

Fulfilling that promise, Mandl said, will take plenty of effort by Apple, health systems and policymakers. Read more at link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.